What is the difference between BIG, TRANSBIG and MINDACT?
TRANSBIG is a research network dedicated to high-level collaboration that will contribute dramatically to advancing individualized treatment for breast cancer patients. Among its many strengths is the fact that it is linked to an already existing network of groups around the world that conduct large breast cancer clinical trials together – the Breast International Group (BIG). In this way, the connection is guaranteed between what scientists learn in the laboratory and what physicians and patients decide together about treatments in the clinic. MINDACT refers to the first clinical trial conducted by TRANSBIG. TRANSBIG is built on the existing BIG network, by incorporating translational research components into existing BIG trials. Both networks are coordinated by the BIG Headquarters in Brussels.
